Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003950 · ClinicalTrials.gov registry record · Phase 2
Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal Cancer
A Phase 2 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT00003950 is a Phase 2 study that has completed, run by University of Chicago. The registered enrollment target is 16 participants.
The verdict
NCT00003950, a Phase 2 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Cyclosporine may relieve the diarrhea caused by irinotecan. PURPOSE: Phase II trial to study the effectiveness of irinotecan and cyclosporine in treating patients who have metastatic, advanced, or locally recurrent colorectal cancer that has not responded to fluorouracil.
Interventions
- DRUG cyclosporine
- DRUG CPT-11
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2000-01 |
| Est. Completion | 2005-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003950
The ClinicalTrials.gov registry entry for NCT00003950 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which cyclosporine is the first listed.
NCT00003950 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003950 about?
NCT00003950 is a clinical study titled "Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Cyclosporine may relieve the diarrhea caused by irinotecan. PURPOSE: Phase II trial to study the effectiveness of irinotecan and cyclosporine in treating patients who have metasta...
What is the current status of trial NCT00003950?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2000-01. Estimated completion is 2005-01.
What interventions are being tested in trial NCT00003950?
The interventions under investigation include: cyclosporine (DRUG), CPT-11 (DRUG).
Who is sponsoring clinical trial NCT00003950?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.